RxDoctor Payments Data

Ofer Levy

Pediatric Infectious Diseases · Boston, MANPI 1316034663

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $30,030 of the $41,197 with a category attached, or 72.9%. 7 manufacturers reported payments, led by Takeda Pharmaceuticals U.S.A., Inc. at 33.0% of the total. Reporting peaked in 2023 at $19,119 and has fallen 86.4% since, to $2,600 in 2025.

$41,197in general payments, 2019–2025

Across 32 payments — averaging $1287.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Takeda Pharmaceuticals U.S.A., Inc.$14K
  • GSK$8K
  • UCB SA$7K
  • Pfizer$6K
  • Merck$3K
  • Sanofi US Services Inc.$2K
  • plus $2K from 1 others
$1,934,021in research payments, 2019–2025

Across 18 payments — averaging $107,446 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • GSK$1.6M
  • Pfizer$320K
  • Sanofi Pasteur Inc.$2K

What the payments were for

  • Consulting fees$30,03073%
  • Speaking & faculty fees$3,0007%
  • Travel & lodging$8,03219%
  • Food & beverage$1350%

General payments by program year

19
20
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Takeda Pharmaceuticals U.S.A., Inc.1$13,598
GSK22$8,245
UCB SA1$6,840
Pfizer5$5,522
Merck1$3,400
Sanofi US Services Inc.1$2,000
AstraZeneca1$1,593

How this compares

$41,197 in reported general payments places this provider in the 85th percentile of 29 pediatric infectious diseases providers in Massachusetts.

See all pediatric infectious diseases providers in Massachusetts →

Other pediatric infectious diseases in Boston

See the full list for Massachusetts →

Where these figures come from

Is this you, or does something look wrong? →